BioTime Inc (BTX)-医療機器分野:企業M&A・提携分析

◆英語タイトル:BioTime Inc (BTX) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA8011335
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月22日
◆ページ数:72
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
BioTime Inc (BioTime) is a biotechnology company which focuses on regenerative medicine and plasma volume expanders. The company’s Hextend is a blood plasma volume expander used for the treatment of hypovolemia in surgery, emergency trauma treatment, and other applications. It is also developing Renevia facial aesthetics product, a potential treatment for facial lipoatrophy; AST-VAC1 and AST-VAC2 autologous (patient-specific) cancer vaccines; Premvia for tendon and wound-management applications; OpRegen for the treatment of dry form of age-related macular degeneration (AMD); AST-OPC1 for spinal cord injury rehabilitation; HyStem hydrogel products; and mobile health software products. BioTime’s products can be used in oncology, neuroscience, orthopedics and blood and vascular diseases. Its products are developed on its pluripotent stem technology. The company has operations in the US, Hong Kong, Israel and Singapore. BioTime is headquartered in California, the US.

BioTime Inc (BTX) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
BioTime Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
BioTime Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
BioTime Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
BioTime Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 9
BioTime Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
BioTime Inc, Medical Equipment, Deal Details 12
Venture Financing 12
LifeMap Solutions Raises US$5 Million In Seed Financing 12
Partnerships 13
OncoCyte Enters into Licensing Agreement with Cornell University for PanC-Dx 13
OncoCyte Enters into Co-Development Agreement with Abcodia for PanC-Dx Test 14
OncoCyte Expands Co-Development Agreement with Wistar Institute 15
BioTime Enters Into Distribution Agreement With USCN Life Science 16
Heraeus Medical Enters into Licensing Agreement with OrthoCyte 17
OncoCyte Enters into Licensing Agreement with Wistar Institute of Anatomy and Biology 18
BioTime Enters Into Option Licensing Agreement With USCN Life Science 20
Equity Offering 21
BioTime Completes Public Offering of Shares for USD28.8 Million 21
OncoCyte Plans to Raise up to USD50 Million in Public Offering of Securities 23
OncoCyte Raises USD5.7 Million in Private Placement of Shares upon Exercise of Warrants 24
Biotime Plans to Raise up to USD15 Million in Public Offering of Shares 25
BioTime to Raise up to USD25 Million in Private Placement of Shares 27
OncoCyte Raises USD2 Million in Private Placement of Shares upon Exercise of Warrants 28
OncoCyte Raises USD3.2 Million in Private Placement of Units 29
OncoCyte Raises USD7.3 Million in Private Placement of Units 30
BioTime Raises USD5 Million in Private Placement of Shares 31
BioTime Raises USD20.4 Million in Private Placement of Shares 32
OncoCyte Raises USD3.3 Million in Private Placement of Shares 34
BioTime Completes Private Placement Of Shares For US$6.4 Million 35
BioTime Announces Public Offering Of Shares For Up To US$15 Million 36
BioTime Completes Public Offering Of Shares For US$3.5 Million 37
BioTime Completes Private Placement Of Units For US$9 Million 38
BioTime Accelerates Closing Date For Second Tranche Of Private Placement Of Shares For US$3 Million 39
BioTime Announces Private Placement Of Common Stock 41
BioTime Completes Private Placement For US$3.6 Million 42
Acquisition 43
OrthoCyte Completes Acquisition Of Glycosan BioSystems 43
BioTime Inc – Key Competitors 45
BioTime Inc – Key Employees 46
BioTime Inc – Locations And Subsidiaries 47
Head Office 47
Other Locations & Subsidiaries 47
Joint Venture 48
Recent Developments 49
Financial Announcements 49
Nov 09, 2017: BioTime Reports Third Quarter Results and Recent Corporate Accomplishments 49
Aug 02, 2017: BioTime Reports Second Quarter Results and Recent Accomplishments 51
May 10, 2017: BioTime Reports First Quarter Results and Recent Corporate Accomplishments 53
Mar 16, 2017: BioTime Reports Fourth Quarter and Fiscal Year 2016 Financial Results and Recent Corporate Accomplishments 55
Feb 21, 2017: BioTime Reports Pro Forma Gain on Deconsolidation of OncoCyte Subsidiary 58
Nov 03, 2016: BioTime Reports Third Quarter Results and Recent Clinical Progress 59
Aug 09, 2016: BioTime Reports Second Quarter Results and Recent Corporate Accomplishments 61
May 10, 2016: BioTime Reports First Quarter Results and Recent Corporate Accomplishments 63
Corporate Communications 66
Jul 13, 2017: BioTime Subsidiary AgeX Therapeutics Appoints Aubrey de Grey, Ph.D. as VP of New Technology Discovery 66
Feb 07, 2017: BioTime Appoints Industry Veteran, Stephana Patton, Ph.D., J.D., as General Counsel 67
Oct 31, 2016: BioTime Appoints Industry Veteran Jim Knight as Senior Vice President, Head of Corporate Development 68
Product News 69
May 11, 2017: BioTime Presents Retinal Restoration Data at ARVO 69
Aug 15, 2016: BioTime Announces Issuance of 31 New Patents to Strengthen its Patent Portfolio in Regenerative Medicine 70
Jun 28, 2016: Mount Sinai Launches Mobile Healthcare App Developed with LifeMap Solutions, a subsidiary of BioTime 71
Appendix 72
Methodology 72
About GlobalData 72
Contact Us 72
Disclaimer 72

List of Tables
BioTime Inc, Medical Equipment, Key Facts, 2016 2
BioTime Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
BioTime Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
BioTime Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
BioTime Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
BioTime Inc, Deals By Market, 2011 to YTD 2017 9
BioTime Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
LifeMap Solutions Raises US$5 Million In Seed Financing 12
OncoCyte Enters into Licensing Agreement with Cornell University for PanC-Dx 13
OncoCyte Enters into Co-Development Agreement with Abcodia for PanC-Dx Test 14
OncoCyte Expands Co-Development Agreement with Wistar Institute 15
BioTime Enters Into Distribution Agreement With USCN Life Science 16
Heraeus Medical Enters into Licensing Agreement with OrthoCyte 17
OncoCyte Enters into Licensing Agreement with Wistar Institute of Anatomy and Biology 18
BioTime Enters Into Option Licensing Agreement With USCN Life Science 20
BioTime Completes Public Offering of Shares for USD28.8 Million 21
OncoCyte Plans to Raise up to USD50 Million in Public Offering of Securities 23
OncoCyte Raises USD5.7 Million in Private Placement of Shares upon Exercise of Warrants 24
Biotime Plans to Raise up to USD15 Million in Public Offering of Shares 25
BioTime to Raise up to USD25 Million in Private Placement of Shares 27
OncoCyte Raises USD2 Million in Private Placement of Shares upon Exercise of Warrants 28
OncoCyte Raises USD3.2 Million in Private Placement of Units 29
OncoCyte Raises USD7.3 Million in Private Placement of Units 30
BioTime Raises USD5 Million in Private Placement of Shares 31
BioTime Raises USD20.4 Million in Private Placement of Shares 32
OncoCyte Raises USD3.3 Million in Private Placement of Shares 34
BioTime Completes Private Placement Of Shares For US$6.4 Million 35
BioTime Announces Public Offering Of Shares For Up To US$15 Million 36
BioTime Completes Public Offering Of Shares For US$3.5 Million 37
BioTime Completes Private Placement Of Units For US$9 Million 38
BioTime Accelerates Closing Date For Second Tranche Of Private Placement Of Shares For US$3 Million 39
BioTime Announces Private Placement Of Common Stock 41
BioTime Completes Private Placement For US$3.6 Million 42
OrthoCyte Completes Acquisition Of Glycosan BioSystems 43
BioTime Inc, Key Competitors 45
BioTime Inc, Key Employees 46
BioTime Inc, Subsidiaries 47
BioTime Inc, Joint Venture 48

★海外企業調査レポート[BioTime Inc (BTX)-医療機器分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Siam Makro Public Company Limited (MAKRO):企業の財務・戦略的SWOT分析
    Siam Makro Public Company Limited (MAKRO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Empresaria Group plc (EMR):企業の財務・戦略的SWOT分析
    Empresaria Group plc (EMR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Etablissements Maurel & Prom SA Oil & Gas Exploration and Production Operations and Cost Analysis – 2017
    Etablissements Maurel & Prom SA Oil & Gas Exploration and Production Operations and Cost Analysis - 2017 Summary Etablissements Maurel & Prom SA Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comp …
  • Chiesi USA Inc:企業の戦略的SWOT分析
    Chiesi USA Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • WPG Holdings Limited:企業の戦略・SWOT・財務情報
    WPG Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary WPG Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • MEDICREA Group (ALMED):医療機器:M&Aディール及び事業提携情報
    Summary MEDICREA Group (MEDICREA) is a medical equipment company that provides surgical solutions to neurosurgeons and orthopedic surgeons. The company designs, manufactures and distributes proprietary technologies related to patient specific spinal surgery. It offers products such as polyaxial spin …
  • Xtract Resources Plc (XTR):企業の財務・戦略的SWOT分析
    Summary Xtract Resources Plc (Xtract Resources), formerly Xtract Energy plc is a mining and mineral exploration and development company that offers mineral resources. The company acquires, explores, manages, operates, produces, mines, extracts, and develops gold and mineral resource deposit properti …
  • Cloud Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Cloud Pharmaceuticals Inc (Cloud Pharmaceuticals), formerly TeraDiscoveries Inc is a drug development company that designs and develops novel drugs and therapies for cancer, inflammation, CNS disorders, and rare diseases. The company offers molecular designs of ligands through its proprietar …
  • Walchandnagar Industries Ltd
    Walchandnagar Industries Ltd - Strategy, SWOT and Corporate Finance Report Summary Walchandnagar Industries Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Brigham and Women’s Hospital-医療機器分野:企業M&A・提携分析
    Summary Brigham and Women's Hospital (BWH) is a healthcare service provider that offers patient care services. The hospital offers care coordination, ethics consultation, interpreter services, Kessler library, nutrition, patient and family relations, pharmacy, security and safety, and spiritual care …
  • Sunstone Hotel Investors, Inc.:企業のM&A・事業提携・投資動向
    Sunstone Hotel Investors, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Sunstone Hotel Investors, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers a …
  • Med BioGene Inc (MBI):企業の財務・戦略的SWOT分析
    Med BioGene Inc (MBI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • JA Solar Holdings Co Ltd (JASO):企業の財務・戦略的SWOT分析
    JA Solar Holdings Co Ltd (JASO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Shanghai Zhenhua Heavy Industries Co., Ltd.:企業の戦略・SWOT・財務情報
    Shanghai Zhenhua Heavy Industries Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Shanghai Zhenhua Heavy Industries Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation …
  • Covanta Holding Corp (CVA):企業の財務・戦略的SWOT分析
    Covanta Holding Corp (CVA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Savola Group Co:企業の戦略・SWOT・財務情報
    Savola Group Co - Strategy, SWOT and Corporate Finance Report Summary Savola Group Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • de Volksbank NV:企業の戦略・SWOT・財務情報
    de Volksbank NV - Strategy, SWOT and Corporate Finance Report Summary de Volksbank NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Rentokil Initial plc (RTO):企業の財務・戦略的SWOT分析
    Rentokil Initial plc (RTO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Grupo Televisa S.A.B.:企業の戦略・SWOT・財務分析
    Grupo Televisa S.A.B. - Strategy, SWOT and Corporate Finance Report Summary Grupo Televisa S.A.B. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Naspers Limited:企業の戦略・SWOT・財務分析
    Naspers Limited - Strategy, SWOT and Corporate Finance Report Summary Naspers Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆